このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

DBS イメージングベースのプログラミングと閾値評価ベースのプログラミング (DBS-ITAP)

2026年11月6日 更新者:Rob M.A. de Bie、Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

パーキンソン病に対する脳深部刺激の画像ベースのプログラミングと閾値評価ベースのプログラミングを比較するランダム化対照試験

The goal of this single-center prospective, randomized, open-label clinical trial is to compare the effectiveness of imaging-based DBS programming with threshold assessment-based DBS programming in patients with Parkinson's disease and motor response fluctuations.

The main question the study aims to answer is:

Is the improvement of motor symptoms in the OFF-drug phase following STN DBS for Parkinson's disease, using imaging-based DBS programming only, non-inferior to the improvement of motor symptoms following DBS programming with threshold assessment at six months follow-up?

Participants will be randomized to imaging-based programming or to threshold assessment-based programming. The main clinical outcome is motor symptoms; secondary outcomes are level of physical disability and quality of life, among others.

調査の概要

状態

完了

条件

介入・治療

詳細な説明

Rationale:

Deep Brain Stimulation (DBS) of the subthalamic nucleus (STN) is an established treatment for disabling motor symptoms of Parkinson's disease (PD). Correct programming of DBS settings to provide optimal stimulation within the target region is crucial for a successful clinical outcome. To date, programming DBS settings is based on the selection of contact point(s) and stimulation parameters with standardized threshold assessments: for each contact point the current is increased in small steps and the severity of motor symptoms and possible adverse effects are assessed with each step. This process is challenging and time consuming because of the vast number of possible parameter combinations. Furthermore, individual variation in patient anatomy, placement of DBS leads and the occurrence of adverse effects must be considered. This results in long programming sessions that can be exhausting for patients and often leads to inconclusive results due to fatigue. Imaging techniques have been improved greatly over the years and could be useful for programming of DBS settings based on patient-specific anatomy.

Objective:

The aim of this study is to determine whether imaging-based DBS programming for the treatment of Parkinson's motor symptoms in STN DBS is non-inferior to the current standard practice of clinical threshold assessment-based DBS programming.

Study design:

The study is a single-center prospective, randomized, open-label, blinded end-point (PROBE design) clinical trial. Following surgery for DBS implantation, in total 132 patients will be randomized in a 1:1 ratio to initial imaging-based DBS programming (Imaging group) or to DBS programming based on initial threshold assessment (Threshold group). Follow-up is six months and consists of 3 study visits.

Study population:

Patients are eligible for the trial if they will have bilateral STN DBS for Parkinson motor symptoms at Amsterdam UMC.

Interventions:

In both groups (i.e., Imaging and Threshold), DBS programming will start two to three weeks after DBS surgery. For the DBS programming patients are admitted in the hospital for a day while they are off Parkinson medication.

Imaging group:

With the use imaging investigators are capable to visualize the location of the DBS lead within the individual's segmented anatomy and volume of tissue activated (VTA; i.e., the tissue enclosed within an iso-surface of the activation function), this may have the potential to improve programming of the stimulation parameters and outcomes. For this, the postoperative CT-scan is used to localize the DBS leads and the surrounding anatomic structures are reconstructed with the patient's preoperative MRI scan. Based on the patient-specific anatomy the DBS settings (appropriate contacts, amplitude, and pulse width) can be determined that produce the ideal VTA within the target and minimalizing stimulation of the surrounding structures. These settings can then be used as starting point for the programming of the stimulation parameters.

Threshold group:

Each DBS-electrode has four to 16 contact points, close to the tip, from where electrical current can be emitted. When programming DBS, the contact point or combination of contact points used for stimulation and the optimal electrical stimulation parameters are chosen. Two to three weeks after the surgery the clinician turns on the DBS. For this purpose, the patient is admitted to the hospital, and the initial threshold assessment is performed for each contact point. A crucial step in this process is to determine for each separate contact point, the amount of current needed to generate symptomatic improvement and the amount of current that generates adverse effects. To determine these thresholds, current is increased with 0.5 milliampere (mA) steps from 0 to approximately 5.0 mA, sequentially for each contact point, and the severity of Parkinson symptoms and possible adverse effects are assessed with each step. For this threshold-assessment, patients have to be off Parkinson medication (OFF-drug phase). Based on the threshold-assessments the active contact point(s) and stimulation parameters are selected. The DBS current is usually gradually increased over weeks to months with corresponding adjustments of the pharmacological treatment. For patients with bilateral DBS and four contact points on each electrode, the threshold-assessment takes about three hours.

The patient has a 50% chance of being randomized to initial imaging-based DBS programming (i.e., Imaging group). The expected benefit for this group is that they will not need the threshold-assessment and therefore have less burden due to less hospital visits for the programming. There are no extra risks associated with participation in this study. If the stimulation parameters found with imaging-based programming only do not yield enough effect in the Imaging group, the healthcare professionals can choose to execute the threshold-assessment for these patients.

Impact:

The results of the study may well contribute to reducing the burden of DBS treatment. If imaging-based programming is non-inferior to threshold assessment-based programming, this may result in more efficient programming sessions with reduced programming time (less use of health-care resources) and less discomfort for patients.

研究の種類

介入

入学 (実際)

132

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • North Holland
      • Amsterdam、North Holland、オランダ、1105 AZ
        • Amsterdam UMC location AMC

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Parkinson's disease diagnosis based on the clinical diagnostic criteria of Movement Disorder Society
  • Scheduled for DBS screening
  • Age of 18 years or older
  • Understand the Dutch language

Exclusion Criteria:

  • Legally incompetent adults
  • No written informed consent
  • Previous functional stereotactic neurosurgery
  • Dementia
  • Current depression or psychosis

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
実験的:Imaging-based

66 patients with Parkinson's disease will receive imaging-based DBS programming

Preferred contact point(s) and settings for DBS programming will be determined based on the visualization of the electrodes in the patient-specific anatomy and the volume of tissue activated (VTA; i.e., the tissue enclosed within an iso-surface of the activation function). This will be determined with help of the software program Brainlab with the GUIDE XT module.

アクティブコンパレータ:Threshold assessment-based

66 patients with Parkinson's disease will receive DBS programming based on the threshold assessment

The preferred contact point(s) and settings for DBS programming will be determined according to current clinical practice. During the threshold assessment, the amount of electrical current needed to generate symptomatic improvement and the amount of electrical current needed to generate adverse-effects are determined for every contact point of both DBS leads by increasing current with 0.5 mA steps from 0 to approximately 5.0 mA. With each step, severity of Parkinson symptoms and presence of possible adverse-effects are assessed. For each side (i.e., left and right), the contact point with the most favorable trade-off between clinical improvement and adverse effects will be used for stimulation.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) III in OFF phase
時間枠:Change from baseline to 6 months of DBS.

The MDS-UPDRS III measures severity of Parkinson's disease. The scores range between 0 - 132, higher scores indicating worse motor symptoms.

Change from baseline to 6 months of DBS.

二次結果の測定

結果測定
メジャーの説明
時間枠
MDS-UPDRS III in ON phase
時間枠:Change from baseline to 6 months of DBS.

The MDS-UPDRS III measures severity of Parkinson's disease. The scores range between 0 - 132, higher scores indicating worse motor symptoms.

Change from baseline to 6 months of DBS.
MDS-UPDRS IV
時間枠:Change from baseline to 6 months of DBS.

Part IV of the MDS-UPDRS evaluates two motor complications: dyskinesia duration and severity and motor fluctuations by means of six questions administered by a healthcare professional. The fourth part ranges from 0 to 24, with a higher score indicating greater disability.

Change from baseline to 6 months of DBS.
MDS-UPDRS I
時間枠:Change from baseline to 6 months of DBS.

Part I of the MDS-UPDRS evaluates the non-motor impact on patients' experiences of daily living by means of questions administered by a healthcare professional and self-administered questions. The first part ranges from 0 to 52, with a higher score indicating greater disability.

Change from baseline to 6 months of DBS.
MDS-UPDRS II in ON phase
時間枠:Change from baseline to 6 months of DBS.

Part II of the MDS-UPDRS evaluates motor experiences in daily living by means of a self-administered questionnaire. The second part ranges from 0 to 52 with a higher score indicating greater disability.

Change from baseline to 6 months of DBS.
Academic Medical Center Linear Disability Score (ALDS)
時間枠:Change from baseline to 6 months of DBS.

The ALDS measures the disability status of patients with a broad range of diseases. It is expressed by the ability to perform activities in daily living and each item is scored separately. The scores range between 0 - 100, lower scores indicating more disability.

Change from baseline to 6 months of DBS.
Parkinson's Disease Questionnaire 39 (PDQ-39)
時間枠:Change from baseline to 6 months of DBS.

The PDQ-39 evaluates the quality of life by means of a questionnaire containing 39 items and eight dimensions (i.e., mobility, activities of daily living, emotional well-being, stigma, social support, cognitions, communication, and bodily discomfort). The total score is the sum of the eight different dimensions and yields a score between 0 and 100. A higher score indicates less quality of life.

Change from baseline to 6 months of DBS.
Patient satisfaction of the outcome of treatment
時間枠:At 6 months of DBS

The degree of satisfaction scored by the patient on a 5-point Likert scale, with higher scores indicating higher experienced satisfaction.

At 6 months of DBS
Patient evaluation of the burden of therapy
時間枠:At 6 months of DBS

The degree of experienced burden scored by the patient on a 5-point Likert scale, with higher scores indicating higher experienced burden.

At 6 months of DBS
Adverse effects
時間枠:At 6 months of DBS

Number and sort of adverse effects observed during six months follow-up after DBS.

At 6 months of DBS
Use of care
時間枠:At 6 months of DBS

Total contact moments (via telephone or in hospital) during six months follow-up after DBS.

At 6 months of DBS
Total duration of programming sessions
時間枠:At 6 months of DBS

Combined duration of programming sessions during the follow-up period after DBS.

At 6 months of DBS
Final DBS settings
時間枠:At 6 months of DBS

Final stimulation parameters at 6 months after follow-up.

At 6 months of DBS

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Rob de Bie, Prof、Amsterdam UMC

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年1月3日

一次修了 (実際)

2026年10月19日

研究の完了 (実際)

2026年10月19日

試験登録日

最初に提出

2024年1月2日

QC基準を満たした最初の提出物

2024年1月23日

最初の投稿 (実際)

2024年1月25日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月12日

QC基準を満たした最後の更新が送信されました

2026年11月6日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • NL84601.018.23

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

All individual participant data that underlie results in the publication will be made available

IPD 共有時間枠

It will be made available one year after the last study visit of the last participant

IPD 共有アクセス基準

Upon request

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP
  • CSR

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。